Gemifloxacin for community-acquired pneumonia

被引：6

作者：

Lode, Hartmut M. ^{[1
,2
]}

Schmidt-Ionas, Malina ^{[3
]}

Stahlmann, Ralf ^{[1
]}

机构：

[1] Charite, Inst Clin Pharmacol & Toxicol, D-10717 Berlin, Germany

[2] RCMS, D-10717 Berlin, Germany

[3] Helios Hosp Emil von Behring, Dept Chest Dis, D-14165 Berlin, Germany

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 05期

关键词：

CAP; efficacy; gemifloxacin; tolerance;

D O I：

10.1517/13543784.17.5.779

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Newer fluoroquinolones have become an important therapeutic choice in the treatment of community-acquired pneumonia (CAP). Gemifloxacin is one of the newest members of this class of antibiotics and has performed favourably in this indication. Objective: To analyse the microbiological activity, pharmacokinetic/pharmacodynamic properties and clinical activity of gemifloxacin in CAP, as well as the safety reported in controlled clinical studies. Methods: Literature research of English publications in the last 10 years addressing all aspects of gemifloxacin in CAP. Results/conclusions: Gemifloxacin is microbiologically the most active fluoroquinolone against Streptococcus pneumoniae - the leading pathogen of CAP. In several comparative studies gemifloxacin was highly effective and well tolerated in the treatment of mild-to-moderate severe CAP.

引用

页码：779 / 786

页数：8

共 31 条

[1] Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].

Ambrose, Paul G. ;

Bhavnani, Sujata M. ;

Rubino, Christopher M. ;

Louie, Arnold ;

Gumbo, Tawanda ;

Forrest, Alan ;

Drusano, George L. .

CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86

[2] Clinical pharmacodynamics of quinolones [J].

Ambrose, PG ;

Bhavnani, SM ;

Owens, RC .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :529-+

[3] Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia [J].

Anderson, KB ;

Tan, JS ;

File, TM ;

DiPersio, JR ;

Willey, BM ;

Low, DE .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :376-381

[4] Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [J].

不详 .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) :388-416

[5] A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context [J].

Ball, P ;

Mandell, L ;

Patou, G ;

Dankner, W ;

Tillotson, G .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (05) :421-429

[6] Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections [J].

Ball, P ;

File, TM ;

Twynholm, M ;

Henkel, T .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) :19-27

[7] Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety [J].

Bhavnani, SM ;

Andes, DR .

PHARMACOTHERAPY, 2005, 25 (05) :717-740

[8] Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].

Brenwald, NP ;

Appelbaum, P ;

Davies, T ;

Gill, MJ .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (02) :140-143

[9]

Clinical and Laboratory Standards Institute, 2005, M100S15 CLSI

[10] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].

Davidson, R ;

Cavalcanti, R ;

Brunton, JL ;

Bast, DJ ;

de Azavedo, JCS ;

Kibsey, P ;

Fleming, C ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750

← 1 2 3 4 →